Table 4 Presence of the EGFRvIII mutation is not significantly associated with any clinical characteristics
Clinical Characteristic | EGFRvIII absent (n = 19) | EGFRvIII present (n = 22) | p-value |
|---|---|---|---|
Male - no., (%) | 16 (84%) | 18 (82%) | 0.839 (Fisher's) |
Age - mean, (+/-SD) | 53.5 (+/- 11.6) | 55.1 (+/- 14.1) | 0.685 (t-test) |
Oropharynx - no., (%) | 8 (42%) | 6 (27%) | 0.318 (Chi-square) |
Larynx - no., (%) | 6 (32%) | 6 (27%) | 0.763 (Chi-square) |
Oral Cavity - no., (%) | 2 (11%) | 5 (23%) | 0.271 (Fisher's) |
Distant metastasis - no., (%) | 4 (21%) | 12 (55%) | 0.053 (Fisher's) |
Locoregional recurrence - no., (%) | 18 (95%) | 16 (73%) | 0.099 (Fisher's) |
Well-moderately differentiated - no., (%) | 15 (79%) | 14 (64%) | 0.325 (Fisher's) |
Poorly differentiated - no., (%) | 4 (21%) | 8 (36%) | Â |
Prior chemotherapy - no., (%) | 9 (47%) | 8 (36%) | 0.476 (Chi-square) |
Prior radiotherapy - no., (%) | 17 (89%) | 22 (100%) | 0.209 (Fisher's) |
Prior surgery - no., (%) | 17 (89%) | 17 (77%) | 0.419 (Fisher's) |
Caucasian - no., (%) | 15 (79%) | 18 (82%) | 0.562 (Fisher's) |
Erlotinib treatment - no., (%) | 12 (63%) | 15 (68%) | 0.735 (Chi-square) |
No erlotinib treatment - no., (%) | 7 (38%) | 7 (32%) | Â |